Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

METABOLIC DISEASE

Who knew? PPARs may act in the brain too

New research shows that a drug conjugate that links the dual PPAR𝛼/𝛾 agonist tesaglitazar to a GLP-1 receptor agonist has superior effects on weight loss and glucose metabolism compared with monotherapy in mice. The conjugate has actions in the hypothalamus that may contribute to its benefits.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Conjugates for the treatment of metabolic disease.

References

  1. Drucker, D. J. Cell Metab. 27, 740–756 (2018).

    Article  CAS  Google Scholar 

  2. Ahrén, B. et al. Diabetes Obes. Metab. 20, 2210–2219 (2018).

    Article  Google Scholar 

  3. Kristensen, S. L. et al. Lancet Diabetes Endocrinol. 7, 776–785 (2019).

    Article  CAS  Google Scholar 

  4. Jastreboff, A. M. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2206038 (2022).

    Article  PubMed  Google Scholar 

  5. Quarta, C. et al. Nat. Metab. https://doi.org/10.1038/s42255-022-00617-6 (2022).

    Article  Google Scholar 

  6. Kalliora, C. & Drosatos, K. J. Cardiovasc. Pharmacol. 76, 514–526 (2020).

    Article  CAS  Google Scholar 

  7. Ryan, K. K. et al. Nat. Med. 17, 623–626 (2011).

    Article  CAS  Google Scholar 

  8. Sarruf, D. A. et al. Endocrinol. 150, 707–712 (2009).

    Article  CAS  Google Scholar 

  9. Adams, J. M. et al. Diabetes 67, 1538–1548 (2018).

    Article  CAS  Google Scholar 

  10. Ludwig, M. Q. et al. Diabetes 70, 1945–1955 (2021).

    Article  CAS  Google Scholar 

  11. MacDougald, O. A. & Lane, M. D. Annu. Rev. Biochem. 64, 345–373 (1995).

    Article  CAS  Google Scholar 

  12. Tontonoz, P. & Spiegelman, B. M. Annu. Rev. Biochem. 77, 289–312 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Randy J. Seeley.

Ethics declarations

Competing interests

R.J.S. receives research support from AstraZeneca, Novo Nordisk and Fractyl. R.J.S. has served as a paid consultant for Novo Nordisk, Scohia, CinRx, ShouTi Pharma and Fractyl. R.J.S. has equity in Calibrate and Rewind. This work was supported by NIH grants to R.J.S. P01DK117821 and P30DK089503. C.J.R. is an employee of AstraZeneca and owns AstraZeneca stock.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Seeley, R.J., Rhodes, C.J. Who knew? PPARs may act in the brain too. Nat Metab 4, 965–966 (2022). https://doi.org/10.1038/s42255-022-00625-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s42255-022-00625-6

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing